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It has been nearly 130 years since Sydney Ringer’s astute
observations on the indispensability of extracellular Ca2 to
eart muscle contraction (1). At the cellular level, we now
now that fluctuations of cytosolic Ca2 are coordinated by
everal myocyte proteins in order to functionally couple the
ardiac action potential to sarcomeric shortening and mito-
hondrial energy production. This elegant myocardial Ca2
cycling demands precise regulation of intracellular Ca2, as
videnced by the numerous examples of cardiac dysfunction
rising from altered expression or activity of Ca2 handling
roteins (2–5). One such protein, S100A1, has attracted the
nterest of cardiac scientists because of its myocardial
nrichment, known interactions with several other Ca2
See page 966
handling proteins, including ryanodine receptors (RyR) and
sarcoplasmic reticulum (SR) Ca2 ATPase (SERCA), and
the observation that its expression is progressively down-
regulated in failing myocardium (6). Furthermore, cardiac-
specific S100A1 deletion accelerated the progression to
heart failure (HF) after myocardial infarction in mice (7),
whereas restoration of S100A1 expression via intracoronary
adenoviral gene delivery to failing rat hearts normalized
contractile performance (8).
In this issue of the Journal, Brinks et al. (9) provide the
first evidence that S100A1 gene delivery can functionally
improve human failing cardiomyocytes. Using ventricular
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isolated and infected with adenovirus encoding S100A1
(Ad-S100A1). The authors show that restoring S100A1
expression improved failing cardiomyocyte fractional short-
ening, relaxation rates, and Ca2 transients compared with
control cells. Moreover, Ad-S100A1 improved both rate-
dependent and -adrenergic–mediated contractile reserve,
while ameliorating markers of abnormal energy metabolism
in isolated cardiomyocytes and mitochondria from failing
hearts. Despite increases in SR Ca2 load, elevated S100A1
expression reduced diastolic SR Ca2 leak and the propen-
sity for aberrant depolarizations.
From a mechanistic standpoint, Brinks et al. (9) propose
that S100A1 enhances failing cardiomyocyte contraction
through improved cytosolic Ca2 handling. In this regard, it
is particularly interesting that the ability of S100A1 to
improve Ca2 transients and pathological shortening-
requency responses occurred without altering either path-
logical decreases in SERCA abundance or increases in
arcolemmal Na/Ca2 exchanger that have been previ-
usly identified as major determinants of these defects in
uman myocardium (10–12). Although detailed proof of
he molecular mechanism of S100A1’s actions is not re-
orted, Brinks et al. speculate that they result from direct
nteraction of S100A1 with SR and mitochondrial proteins
i.e., RyR, SERCA, and F1-ATPase). Recent studies also
ndicate that S100A1 may enhance contractility and relax-
tion dynamics by regulating the interaction between the
arcomeric proteins titin and cardiac actin (13).
These findings represent an exciting initial step toward
onfirming S100A1 as a viable therapeutic target in human
F, concordant with prior data reported in various animal
odels. The physiological difference in Ca2 handling
between human and small mammal cardiomyocytes neces-
sitates such work. The authors rightly caution, however,
against prematurely extrapolating their in vitro, isolated
cardiomyocyte findings to the intact organ or the human
clinical setting. One reason is that S100A1 levels spike in
the plasma after acute myocardial damage (14), and reports
indicate that S100 proteins exert extracellular and perhaps
paracrine effects (15–17), neither of which could be ac-
counted for in the present study of isolated cells. In
addition, S100A1 is also expressed in endothelial cells of the
vasculature, and global deletion of S100A1 produces a
hypertensive phenotype due to impaired nitric oxide–
mediated vasorelaxation (18). This implies that the relative
impact of S100A1 expression on both vascular and cardiac
function remains to be determined.
These concerns aside, Brinks et al. (9) have furnished
important in vitro data showing salutary effects of S100A1
on human myocardium. S100A1 is an especially intriguing
prospect for HF treatment because it appears to serve
critical functions in both the vasculature and the heart, and
interacts with proteins at multiple nodes of the Ca2 cycle
(Fig. 1). In this regard, analogous studies involving virus-
11
975JACC Vol. 58, No. 9, 2011 Belmonte et al.
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cytes (19) inspired successful pre-clinical studies in pigs with
cardiac dysfunction (20) which, in turn, led to encouraging
pilot studies of SERCA gene therapy in humans with
advanced heart failure. These prior studies provide a trans-
lational template and demonstrate the technical feasibility of
myocardial gene therapy that is relevant to the present
studies. Additionally, studies employing SERCA gene ther-
apy and cardiac resynchronization therapy also support the
conceptual argument that some therapies with positive
inotropic effects may ultimately prove beneficial despite the
many positive inotropic agents that have previously failed to
improve outcomes among patients with advanced heart
failure (21). In this context, although further studies and
optimization of gene therapy delivery mode, vector, and
safety profile are warranted, the current report suggests that
S100A1-based gene therapy for HF could one day be
translated to human benefit.
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Figure 1 The Intersections of S100A1 and the Cardiac Ca2 C
Sarcolemmal membrane depolarization opens voltage-gated L-type Ca2 channels,
adjacent ryanodine receptors (RyR) of the sarcoplasmic reticulum (SR), causing a
contracts. Some of the Ca2 released from the SR enters the mitochondria via th
accomplished by removing Ca2 from the cytosol, primarily by SR Ca2 ATPase (S
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